Transglutaminase 2 exacerbates α-synuclein toxicity in mice and yeast

FASEB Journal

Volumn 28, Issue 10, 2014, Pages 4280-4291

  Grosso, Hilary ^a   Woo, Jong Min ^a,c   Lee, Kang Woo ^a,d   Im, Joo Young ^a,e   Masliah, Eliezer ^b   Junn, Eunsung ^a   Mouradian, M Maral ^a  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Korea Institute of Oriental Medicine (KIOM)   (South Korea)

^d Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^e Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

Neuro degeneration; Parkinson's disease; Protein misfolding

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID; PROTEIN C FOS; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; PROTEINASE K; THIOFLAVINE; GUANINE NUCLEOTIDE BINDING PROTEIN; PROTEIN AGGREGATE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BRAIN NERVE CELL; CELL LYSATE; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE ASSOCIATION; DISEASE EXACERBATION; FEMALE; IMMUNOREACTIVITY; IN VIVO STUDY; MALE; MICROGLIA; MOLECULAR WEIGHT; MOUSE; MUS MUSCULUS; NERVE CELL LESION; NERVE FIBER DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SACCHAROMYCES CEREVISIAE; SYNAPSE VESICLE; TRANSGENIC MOUSE; YEAST CELL; ANIMAL; BRAIN; C57BL MOUSE; HUMAN; LOCOMOTION; METABOLISM; NERVE FIBER; PATHOLOGY; PHYSIOLOGY; PROTEINOSIS;

ALPHA-SYNUCLEIN; ANIMALS; ASTROCYTES; BRAIN; GTP-BINDING PROTEINS; HUMANS; LOCOMOTION; MICE; MICE, INBRED C57BL; NERVE FIBERS; PROTEIN AGGREGATES; PROTEIN AGGREGATION, PATHOLOGICAL; SACCHAROMYCES CEREVISIAE; SYNAPTIC VESICLES; TRANSGLUTAMINASES;

EID: 84907699043     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.14-251413     Document Type: Article

References (55)

1. Lee, V. M., and Trojanowski, J. Q. (2006) Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery. Neuron 52, 33-38
2. Goldberg, M. S., and Lansbury, P. T., Jr. (2000) Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease? Nat. Cell Biol. 2, E115-119
3. Cookson, M. R. (2009) alpha-Synuclein and neuronal cell death. Mol. Neurodegener. 4, 9
4. Jeitner, T. M., Pinto, J. T., Krasnikov, B. F., Horswill, M., and Cooper, A. J. (2009) Transglutaminases and neurodegeneration. J. Neurochem. 109(Suppl. 1), 160-166
5. Grosso, H., and Mouradian, M. M. (2012) Transglutaminase 2: biology, relevance to neurodegenerative diseases and therapeutic implications. Pharmacol. Ther. 133, 392-410
6. Campisi, A., Caccamo, D., Li Volti, G., Curro, M., Parisi, G., Avola, R., Vanella, A., and Ientile, R. (2004) Glutamate-evoked redox state alterations are involved in tissue transglutaminase upregulation in primary astrocyte cultures. FEBS Lett. 578, 80-84
7. Filiano, A. J., Bailey, C. D., Tucholski, J., Gundemir, S., and Johnson, G. V. (2008) Transglutaminase 2 protects against ischemic insult, interacts with HIF1beta, and attenuates HIF1 signaling. FASEB J. 22, 2662-2675
8. Junn, E., Ronchetti, R. D., Quezado, M. M., Kim, S. Y., and Mouradian, M. M. (2003) Tissue transglutaminase-induced aggregation of alpha-synuclein: implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies. Proc. Natl. Acad. Sci. U. S. A. 100, 2047-2052
9. Schmid, A. W., Chiappe, D., Pignat, V., Grimminger, V., Hang, I., Moniatte, M., and Lashuel, H. A. (2009) Dissecting the mechanisms of tissue transglutaminase-induced cross-linking of alpha-synuclein: implications for the pathogenesis of Parkinson disease. J. Biol. Chem. 284, 13128-13142
10. Andringa, G., Lam, K. Y., Chegary, M., Wang, X., Chase, T. N., and Bennett, M. C. (2004) Tissue transglutaminase catalyzes the formation of alpha-synuclein crosslinks in Parkinson's disease. FASEB J. 18, 932-934
11. Wilhelmus, M. M., Verhaar, R., Andringa, G., Bol, J. G., Cras, P., Shan, L., Hoozemans, J. J., and Drukarch, B. (2010) Presence of tissue transglutaminase in granular endoplasmic reticulum is characteristic of melanized neurons in Parkinson's disease brain. Brain Pathol. 21, 130-139
12. Vermes, I., Steur, E. N., Jirikowski, G. F., and Haanen, C. (2004) Elevated concentration of cerebrospinal fluid tissue transglutaminase in Parkinson's disease indicating apoptosis. Mov. Disord. 19, 1252-1254
13. Tucholski, J., Roth, K. A., and Johnson, G. V. (2006) Tissue transglutaminase overexpression in the brain potentiates calcium-induced hippocampal damage. J. Neurochem. 97, 582-594
14. Rockenstein, E., Mallory, M., Hashimoto, M., Song, D., Shults, C. W., Lang, I., and Masliah, E. (2002) Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters. J. Neurosci. Res. 68, 568-578
15. Kahle, P. J., Neumann, M., Ozmen, L., Muller, V., Jacobsen, H., Schindzielorz, A., Okochi, M., Leimer, U., van Der Putten, H., Probst, A., Kremmer, E., Kretzschmar, H. A., and Haass, C. (2000) Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha -synuclein in human and transgenic mouse brain. J. Neurosci. 20, 6365-6373
16. Sun, A., Nguyen, X. V., and Bing, G. (2002) Comparative analysis of an improved thioflavin-s stain, Gallyas silver stain, and immunohistochemistry for neurofibrillary tangle demonstration on the same sections. J. Histochem. Cytochem. 50, 463-472
17. Quinn, L. P., Crook, B., Hows, M. E., Vidgeon-Hart, M., Chapman, H., Upton, N., Medhurst, A. D., and Virley, D. J. (2008) The PPARgamma agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B. Br. J. Pharmacol. 154, 226-233
18. Deacon, R. M. (2006) Assessing nest building in mice. Nat. Protoc. 1, 1117-1119
19. Hashimoto, M., Rockenstein, E., Mante, M., Mallory, M., and Masliah, E. (2001) beta-Synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor. Neuron 32, 213-223
20. Masliah, E., Rockenstein, E., Adame, A., Alford, M., Crews, L., Hashimoto, M., Seubert, P., Lee, M., Goldstein, J., Chilcote, T., Games, D., and Schenk, D. (2005) Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron 46, 857-868
21. Su, X., Maguire-Zeiss, K. A., Giuliano, R., Prifti, L., Venkatesh, K., and Federoff, H. J. (2008) Synuclein activates microglia in a model of Parkinson's disease. Neurobiol. Aging 29, 1690-1701
22. Lee, K. W., Chen, W., Junn, E., Im, J. Y., Grosso, H., Sonsalla, P. K., Feng, X., Ray, N., Fernandez, J. R., Chao, Y., Masliah, E., Voronkov, M., Braithwaite, S. P., Stock, J. B., and Mouradian, M. M. (2011) Enhanced phosphatase activity attenuates alpha-Synucleinopathy in a mouse model. J. Neurosci. 31, 6963-6971
23. Kurz, A., May, C., Schmidt, O., Muller, T., Stephan, C., Meyer, H. E., Gispert, S., Auburger, G., and Marcus, K. (2011) A53Talpha-synuclein-overexpression in the mouse nigrostriatal pathway leads to early increase of 14-3-3 epsilon and late increase of GFAP. J. Neural Transm. 119, 297-312
24. Kajihara, H., Tsutsumi, E., Kinoshita, A., Nakano, J., Takagi, K., and Takeo, S. (2001) Activated astrocytes with glycogen accumulation in ischemic penumbra during the early stage of brain infarction: immunohistochemical and electron microscopic studies. Brain Res. 909, 92-101
25. Harada, A., Teng, J., Takei, Y., Oguchi, K., and Hirokawa, N. (2002) MAP2 is required for dendrite elongation, PKA anchoring in dendrites, and proper PKA signal transduction. J. Cell Biol. 158, 541-549
26. Iwata, M., Muneoka, K. T., Shirayama, Y., Yamamoto, A., and Kawahara, R. (2005) A study of a dendritic marker, microtubuleassociated protein 2 (MAP-2), in rats neonatally treated neurosteroids, pregnenolone and dehydroepiandrosterone (DHEA). Neurosci. Lett. 386, 145-149
27. Zhang, X., Dong, F., Mayer, G. E., Bruch, D. C., Ren, J., and Culver, B. (2007) Selective inhibition of cyclooxygenase-2 exacerbates methamphetamine-induced dopamine depletion in the striatum in rats. Neuroscience 150, 950-958
28. Koob, A. O., Ubhi, K., Paulsson, J. F., Kelly, J., Rockenstein, E., Mante, M., Adame, A., and Masliah, E. (2010) Lovastatin ameliorates alpha-synuclein accumulation and oxidation in transgenic mouse models of alpha-synucleinopathies. Exp. Neurol. 221, 267-274
29. Kano, T., Suzuki, Y., Shibuya, M., Kiuchi, K., and Hagiwara, M. (1995) Cocaine-induced CREB phosphorylation and c-Fos expression are suppressed in Parkinsonism model mice. Neuroreport 6, 2197-2200
30. Palop, J. J., Jones, B., Kekonius, L., Chin, J., Yu, G. Q., Raber, J., Masliah, E., and Mucke, L. (2003) Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits. Proc. Natl. Acad. Sci. U. S. A. 100, 9572-9577
31. Sager, T. N., Kirchhoff, J., Mork, A., Van Beek, J., Thirstrup, K., Didriksen, M., and Lauridsen, J. B. (2010) Nest building performance following MPTP toxicity in mice. Behav. Brain Res. 208, 444-449
32. Outeiro, T. F., and Lindquist, S. (2003) Yeast cells provide insight into alpha-synuclein biology and pathobiology. Science 302, 1772-1775
33. Lam, H. A., Wu, N., Cely, I., Kelly, R. L., Hean, S., Richter, F., Magen, I., Cepeda, C., Ackerson, L. C., Walwyn, W., Masliah, E., Chesselet, M. F., Levine, M. S., and Maidment, N. T. (2011) Elevated tonic extracellular dopamine concentration and altered dopamine modulation of synaptic activity precede dopamine loss in the striatum of mice overexpressing human alphasynuclein. J. Neurosci. Res. 89, 1091-1102
34. Clayton, D. F., and George, J. M. (1999) Synucleins in synaptic plasticity and neurodegenerative disorders. J. Neurosci. Res. 58, 120-129
35. Auluck, P. K., Caraveo, G., and Lindquist, S. (2010) alpha-Synuclein: membrane interactions and toxicity in Parkinson's disease. Annu. Rev. Cell Dev. Biol. 26, 211-233
36. Butterfield, S. M., and Lashuel, H. A. (2010) Amyloidogenic protein-membrane interactions: mechanistic insight from model systems. Angew. Chem. Int. Ed. Engl. 49, 5628-5654
37. Nemes, Z., Petrovski, G., Aerts, M., Sergeant, K., Devreese, B., and Fesus, L. (2009) Transglutaminase-mediated intramolecular cross-linking of membrane-bound alpha-synuclein promotes amyloid formation in Lewy bodies. J. Biol. Chem. 284, 27252-27264
38. Siegel, M., and Khosla, C. (2007) Transglutaminase 2 inhibitors and their therapeutic role in disease states. Pharmacol. Ther. 115, 232-245
39. Gundemir, S., Colak, G., Tucholski, J., and Johnson, G. V. (2012) Transglutaminase 2: A molecular Swiss army knife. Biochim. Biophys. Acta 1823, 406-419
40. Karpuj, M. V., Becher, M. W., Springer, J. E., Chabas, D., Youssef, S., Pedotti, R., Mitchell, D., and Steinman, L. (2002) Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat. Med. 8, 143-149
41. McConoughey, S. J., Basso, M., Niatsetskaya, Z. V., Sleiman, S. F., Smirnova, N. A., Langley, B. C., Mahishi, L., Cooper, A. J., Antonyak, M. A., Cerione, R. A., Li, B., Starkov, A., Chaturvedi, R. K., Beal, M. F., Coppola, G., Geschwind, D. H., Ryu, H., Xia, L., Iismaa, S. E., Pallos, J., Pasternack, R., Hils, M., Fan, J., Raymond, L. A., Marsh, J. L., Thompson, L. M., and Ratan, R. R. (2010) Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease. EMBO Mol. Med. 2, 349-370
42. Mastroberardino, P. G., Iannicola, C., Nardacci, R., Bernassola, F., De Laurenzi, V., Melino, G., Moreno, S., Pavone, F., Oliverio, S., Fesus, L., and Piacentini, M. (2002) 'Tissue' transglutaminase ablation reduces neuronal death and prolongs survival in a mouse model of Huntington's disease. Cell Death Differ. 9, 873-880
43. D'Eletto, M., Farrace, M. G., Falasca, L., Reali, V., Oliverio, S., Melino, G., Griffin, M., Fimia, G. M., and Piacentini, M. (2009) Transglutaminase 2 is involved in autophagosome maturation. Autophagy 5, 1145-1154
44. Przedborski, S. (2010) Inflammation and Parkinson's disease pathogenesis. Mov. Disord. 25(Suppl. 1), S55-S57
45. Iismaa, S. E., Mearns, B. M., Lorand, L., and Graham, R. M. (2009) Transglutaminases and disease: lessons from genetically engineered mouse models and inherited disorders. Physiol. Rev. 89, 991-1023
46. Desplats, P., Lee, H. J., Bae, E. J., Patrick, C., Rockenstein, E., Crews, L., Spencer, B., Masliah, E., and Lee, S. J. (2009) Inclusion formation and neuronal cell death through neuronto-neuron transmission of alpha-synuclein. Proc. Natl. Acad. Sci. U. S. A. 106, 13010-13015
47. Lee, H. J., Suk, J. E., Patrick, C., Bae, E. J., Cho, J. H., Rho, S., Hwang, D., Masliah, E., and Lee, S. J. (2010) Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. J. Biol. Chem. 285, 9262-9272
48. Kim, C., Ho, D. H., Suk, J. E., You, S., Michael, S., Kang, J., Joong Lee, S., Masliah, E., Hwang, D., Lee, H. J., and Lee, S. J. (2013) Neuron-released oligomeric alpha-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat. Commun. 4, 1562
49. Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., Lincoln, S., Crawley, A., Hanson, M., Maraganore, D., Adler, C., Cookson, M. R., Muenter, M., Baptista, M., Miller, D., Blancato, J., Hardy, J., and Gwinn-Hardy, K. (2003) alpha- Synuclein locus triplication causes Parkinson's disease. Science 302, 841
50. Farrer, M., Kachergus, J., Forno, L., Lincoln, S., Wang, D. S., Hulihan, M., Maraganore, D., Gwinn-Hardy, K., Wszolek, Z., Dickson, D., and Langston, J. W. (2004) Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann. Neurol. 55, 174-179
51. Chartier-Harlin, M. C., Kachergus, J., Roumier, C., Mouroux, V., Douay, X., Lincoln, S., Levecque, C., Larvor, L., Andrieux, J., Hulihan, M., Waucquier, N., Defebvre, L., Amouyel, P., Farrer, M., and Destee, A. (2004) Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364, 1167-1169
52. Farrer, M., Maraganore, D. M., Lockhart, P., Singleton, A., Lesnick, T. G., de Andrade, M., West, A., de Silva, R., Hardy, J., and Hernandez, D. (2001) alpha-Synuclein gene haplotypes are associated with Parkinson's disease. Hum. Mol. Genet. 10, 1847-1851
53. Chiba-Falek, O., and Nussbaum, R. L. (2001) Effect of allelic variation at the NACP-Rep1 repeat upstream of the alphasynuclein gene (SNCA) on transcription in a cell culture luciferase reporter system. Hum. Mol. Genet. 10, 3101-3109
54. Citron, B. A., Suo, Z., SantaCruz, K., Davies, P. J., Qin, F., and Festoff, B. W. (2002) Protein crosslinking, tissue transglutaminase, alternative splicing and neurodegeneration. Neurochem. Int. 40, 69-78
55. Smethurst, P. A., and Griffin, M. (1996) Measurement of tissue transglutaminase activity in a permeabilized cell system: its regulation by Ca2+ and nucleotides. Biochem. J. 313, 803-808